Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Average Recommendation of "Buy" by Brokerages

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) have been assigned a consensus recommendation of "Buy" from the five brokerages that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $13.22.

NAGE has been the topic of a number of analyst reports. Roth Capital reiterated a "buy" rating and set a $23.00 price objective (up from $10.00) on shares of Niagen Bioscience in a research note on Friday, June 6th. Canaccord Genuity Group increased their price target on shares of Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Finally, Wall Street Zen downgraded shares of Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 2nd.

Institutional Investors Weigh In On Niagen Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Prudential Financial Inc. boosted its position in Niagen Bioscience by 247.2% in the fourth quarter. Prudential Financial Inc. now owns 79,215 shares of the company's stock valued at $420,000 after buying an additional 56,400 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Niagen Bioscience by 2.8% in the 4th quarter. JPMorgan Chase & Co. now owns 341,221 shares of the company's stock valued at $1,810,000 after acquiring an additional 9,305 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Niagen Bioscience by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,154,778 shares of the company's stock valued at $6,128,000 after acquiring an additional 5,186 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Niagen Bioscience during the 4th quarter valued at $144,000. Finally, Wells Fargo & Company MN grew its position in Niagen Bioscience by 42.1% during the 4th quarter. Wells Fargo & Company MN now owns 23,137 shares of the company's stock worth $123,000 after acquiring an additional 6,856 shares during the last quarter. 15.41% of the stock is owned by institutional investors.

Niagen Bioscience Price Performance

NAGE stock opened at $9.61 on Friday. Niagen Bioscience has a fifty-two week low of $2.63 and a fifty-two week high of $14.69. The stock has a market capitalization of $756.98 million, a price-to-earnings ratio of 45.76 and a beta of 2.12. The business's fifty day moving average price is $11.79 and its two-hundred day moving average price is $8.29.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.04 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. The business had revenue of $31.12 million for the quarter, compared to analyst estimates of $28.55 million. Niagen Bioscience had a net margin of 15.24% and a return on equity of 25.53%.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.